Enveric Biosciences Inc. (NASDAQ:ENVB) on Tuesday highlighted preclinical findings for its lead candidate EB-003. It pointed to rapid reductions in PTSD-related fear responses, as recent federal policy signals growing support for psychedelic-based mental health treatments. The company said a single dose of EB-003 significantly reduced context-induced freezing behavior within one hour in a validated preclinical PTSD model, suggesting a fast-acting impact on conditioned fear responses.
